Figure 2.

Multiple models of MMR deficiency are selectively sensitive to cytarabine. (A) Cell viability assay of BVEC F7bro and E2 cells exposed to cytarabine for 24 h (P⩽0.0001 using ANOVA). (B) Cell viability assay of LoVo and LoVo+Chr2 cells, following continuous exposure to cytarabine. (C) Box and whisker plot of cytarabine IC50 values obtained from the Sanger Institute data set, stratified by MSI status. (P=0.0388 using two-tailed t-test). (D) Waterfall plot of cytarabine IC50 values in CRC cell lines obtained from the same data set, stratified by MSI status (P=0.0474 using two-tailed t-test). (E(i)) Survival curves from cell viability assays of A2780cp70 a2 and e1 cells transfected with non-targeting control siRNA or siRNA targeting MLH1, and continuously exposed to various concentrations of cytarabine, vs control, 48 h after transfection. Assays were performed in triplicate or quadruplicate. Error bars represent the s.e.m. (E(ii)) Immunoblot of MLH1 expression in cell lysates obtained from this experiment, with β-actin as loading control.